Key Takeaways Tyler Technologies is set to report Q4 results on Feb. 11, with revenues seen up 8.96% year over year.TYL's subscription revenues are expected to rise 14.7% as public-sector clients shift to SaaS platforms.Software licenses and maintenance revenues are projected to decline amid the ongoing transition to SaaS.Tyler Technologies, Inc. (TYL) is scheduled to report fourth-quarter 2025 results on Feb. 11, after market close.The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $589. ...

Key Takeaways CBRE set to report Q4 earnings on Feb. 12, coming off four straight consensus beats, with an average of 8.5%.CBRE is likely to have benefited from higher contractual revenues, outsourcing demand and diversification.Revenues are expected to rise 10.65% to $11.51B, with Advisory Services at $2.77B and Building Ops at $6.32B.CBRE Group, Inc. (CBRE) , the global leader in real estate services, is set to announce its fourth-quarter 2025 earnings on Feb. 12, before the bell. The company has establis ...

Key Takeaways HSBC and other UK lenders raised mortgage rates even as the Bank of England kept its policy rate unchanged.BCS and peers may see wider net interest margins as higher lending rates tend to boost profitability.EWU offers diversified exposure to UK banks and builders positioned to gain from higher mortgage rates.The UK housing market has taken a surprising turn recently, with central bank policy and major lenders moving in different directions. While the Bank of England (BoE) has opted to hold in ...

Core Insights - The FDA has approved Median Technologies' eyonis, an AI-based lung cancer detection tool, enhancing early cancer diagnosis capabilities [1][4]. Company Overview - Median Technologies is a French medtech company specializing in AI-driven software for medical diagnostics, particularly in lung cancer screening [2]. - The company has a market capitalization of €156 million [3]. Product Details - Eyonis lung cancer screening (LCS) is a computer-aided detection and diagnosis (CADe/CADx) software designed to analyze CT scan imaging data to assist radiologists in identifying and characterizing pulmonary nodules [2]. - The software demonstrated a sensitivity of 93.3%, specificity of 92.4%, and a 99.9% Negative Predictive Value (NPV) in performance testing [4]. Market Impact - Following the FDA approval announcement, Median's stock price surged by 19% to €5.10 ($6.06) at market open, and by 15:00 CET, it had increased by approximately 50% [3]. - The company plans to roll out eyonis LCS in the US through direct sales, strategic partnerships, and integration into existing clinical environments [5]. Financial Aspects - The software is expected to be reimbursed under the current US Medicare framework at a rate between $601 to $700, with plans for broader insurance coverage in the future [6]. - In January 2025, Median received a €37.5 million grant from the European Investment Bank and €10 million from IRIS Capital Investment to support its FDA filing and future European CE mark acquisition, expected in Q2 2026 [7]. Competitive Landscape - Median's FDA clearance follows a similar approval for RevealDX's lung nodule evaluation tool, indicating a growing market for AI-based diagnostic solutions in lung cancer [8].

https://biotechpharmainvestor.substack.comhttps://x.com/StmkrsBackground: Physician involved in clinical research. Investment style: Clinical-stage biotech stocks, long only, both long-term ideas and event-driven trading. My academic/medical background helps me evaluate the scientific fundamentals of biotech stocks.Due to seeking alpha rules and time constraints I cannot cover here all stocks that I am following/trading. I write about such stocks in substack and XAnalyst’s Disclosure: I/we have a beneficial ...

In short: SACRAMENTO, Calif., Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial. Negotiations are moving forward with several pharmaceutical and drug discovery companies. Partnerships and collaborations are imminent. Why? -because Lunai Bioworks operates a closed loop AI system that is truly disruptive (and complementary) to current discovery platforms and that turns complex biology into real-world action in several ways with les ...

ATLANTA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Inovio’s business, operations, and prospects, including allegations that: (i) manufacturing for Inovio’s CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 Biologi ...

Core Insights - Crown Holdings, Inc. specializes in metal packaging production, competing with major players like Ball Corporation and Ardagh Group, with a strong presence in the beverage can and North American tinplate markets [1][6] Financial Performance - UBS set a price target of $126 for Crown Holdings, indicating an 11.62% potential increase from the current trading price of $112.88 [2][6] - The company reported a record adjusted EBITDA of approximately $2.1 billion for 2025, reflecting an 8% increase from the previous year, with a 20% growth over the past three years [2][3][6] - Crown Holdings generated a record free cash flow of $1.15 billion in 2025, accumulating nearly $2 billion over the past two years, supporting its market position and future growth potential [4] Business Strategy - The company's strategic focus on continuous improvement and capacity expansions has significantly contributed to its financial success, with segment income from global beverage can and North American tinplate businesses expanding by over 8% in 2025 [3] - Consistent performance is evident with growth rates of 6% and 7% in 2024 and 2023, respectively [3] Stock Performance - Despite positive financial results, Crown Holdings' stock price has experienced fluctuations, currently trading at $112.88, with a slight decrease of approximately -1.16% today [5] - Over the past year, the stock has seen a high of $115.85 and a low of $75.98, indicating volatility in its performance [5]

The State Street Consumer Staples Select Sector SPDR ETF (NYSEARCA:XLP) and the Fidelity MSCI Consumer Staples Index ETF (NYSEARCA:FSTA) both target U.S. consumer staples, but XLP is much larger and pays a higher yield, while FSTA offers broader diversification and slightly lower volatility. Both XLP and FSTA are designed to give investors exposure to the U.S. consumer staples sector, focusing on companies that provide essential products like food, household goods, and personal care items. This comparison ...

Webster Financial Corporation (NYSE:WBS) operates as a commercial bank across the Northeast, focusing on commercial banking, healthcare financial services, and consumer banking. ...